So, with strong financial results, an exciting pipeline, and potential catalysts on the way, Exelixis looks like a solid stock to buy this month, and a single share is trading hands for less than $34.

AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in ...

AstraZeneca’s presence in South Africa has become a driving force in global health research, contributing significantly to respiratory, cardiovascular, and oncology therapeutic areas. The ...

Rachel Reeves announces the first Labour budget in 14 years, and the first to be delivered by a female Chancellor.

In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials ...

In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare Disease Two Novel Radiopharma Clinical Trials ... The Company is also actively exploring opportunities ...

AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading and diverse pipeline in haematology at the 66th American Society of Hematology (ASH) Annual Meeting ...

This program uses two mechanisms of action, targeting the amylin and calcitonin receptors, which are not represented elsewhere in its pipeline so far. That means it isn't just a rehash ... of weight ...

AstraZeneca has revealed that its top executive in China ... Meanwhile, in a likely welcome diversion from the current ...